A therapeutic approach in an AML-mouse model using an anti-CD44 antibody markedly reduced leukemic repopulation indicating that a disruption of the interaction between LSCs and niche components may offer therapeutic strategies to eliminate quiescent AML LSCs [53]. Here, CD44 is linked to acute myeloid leukemia.